Mucosal insulin vaccination for type 1 diabetes prevention

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue SUPPL. 1, 2008, Pages

  Bonifacio, Ezio ^a   Achenbach, P ^b   Pan, L ^b   Zlegler, A G ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

Author keywords

Autoantigen; Autoimmunity; Genetic prediction of type 1 diabetes; Insulin; Intranasal insulin; Mucosal immunity; Oral vaccination; Type 1 diabetes

Indexed keywords

INSULIN; RECOMBINANT HUMAN INSULIN;

ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY RESPONSE; AUTOIMMUNITY; CELLULAR IMMUNITY; DOSIMETRY; FAMILY HISTORY; FIRST DEGREE FAMILY HISTORY; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MUCOSAL VACCINATION; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; INSULIN; MUCOUS MEMBRANE; VACCINATION;

EID: 54549096939     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081484     Document Type: Review

References (45)

1. French MB, Allison J, Cram DS, Thomas HE, Dempsey-Collier M, Silva A, Georgiou HM, Kay TW, Harrison LC, Lew AM. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997; 46: 34-39
2. Thebault-Baumont K, Dubois-Laforgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, Morin J, Laloux V, Lehuen A, Corel JC, Jami J, Muller S, Boitard C. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003; 111: 851-857
3. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci USA 2003; 100: 10376-10381
4. Jaeckel E, Lipes MA, Boehmer H von. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004; 5: 1028-1035
5. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435: 220-223
6. Krishnamurthy B, Dudek NL, MacKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006; 116: 3258-3265
7. Vardi P, Ziegler AG, Mathews JH, Dib S, Keller RJ, Ricker AT, Wolfsdorf JI, Herskowitz RD, Rabizadeh A, Eisenbarth GS, Soeldner S. Concentration of insulin autoantibodies at onset of type 1 diabetes. Inverse log-linear correlation with age. Diabetes Care 1988; 11: 736-739
8. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABY-DIAB Study. Diabetes 1999; 48: 460-468
9. Kimpimaki T, Kulmala P, Savola K, Kupila A, Korhonen S, Simell T, Ilonen J, Simell O, Knip M. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2002; 87: 4572-4579
10. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89: 3896-3902
11. Colman PG, Steele C, Couper JJ, Beresford SJ, Powell T, Kewming K, Pollard A, Gellert S, Tait B, Honeyman M, Harrison LC. Islet autoimmunity in infants with a type 1 diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000; 43: 203-209
12. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intem Med 2004; 140: 882-886
13. Kimpimaki T, Kupila A, Hamalainen AM, Kukko M, Kulmala P, Savola K, Simell T, Keskinen P, Ilonen J, Simell O, Knip M. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: The finnish type 1 diabetes prediction and prevention study. J Clin Endocrinol Metab 2001; 86: 4782-4788
14. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000; 97: 1701-1706
15. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro) insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114: 589-597
16. Koczwara K, Muller D, Achenbach P, Ziegler AG, Bonifacio E. Identification of insulin autoantibodies of IgA isotype that preferentially target non-human insulin. Clin Immunol 2007; 124: 77-82
17. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113: 451-463
18. Monti P, Scripoli M, Rigamonti A, Mayr A, Jaeger A, Bonfanti R, Chiumello G, Ziegler AG, Bonifacio E. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007; 179: 5785-5792
19. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, Hering BJ, Hafler DA. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435: 224-228
20. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18: 335-343
21. Harrison LC, Hafler DA. Antigen-specific therapy for autoimmune disease. Curr Opin Immunol 2000; 12: 704-711
22. Faria AMC, Weiner HL. Oral tolerance. Immunol Rev 2005; 206: 232-259
23. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun 1994; 7: 655-663
24. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 194: 2167-2174
25. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88: 10252-10256
26. Maron R, Melican NS, Weiner HL. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J Autoimmun 1999; 12: 251-258
27. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996; 93: 956-960
28. Herrath MG von, Dyrberg T, Oldstone MB. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996; 98: 1324-1331
29. Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 2001; 16: 21-28
30. Kupila A, Sipila J, Keskinen P, Simell T, Knip M, Pulkki K, Simell O. Intranasally administered insulin intended for prevention of type 1 diabetes - a safety study in healthy adults. Diabetes Metab Res Rev 2003; 19: 415-420
31. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, Couper JJ, Colman PG. Pancreatic {beta}-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27: 2348-2355
32. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Marechaud R, Bougneres P, Charbonnel B, Sai P. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 2000; 356: 545-549
33. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, Manca Bitti ML, Matteoli MC, Marletti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G. No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000; 43: 1000-1004
34. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-1324
35. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727-1730
36. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28: 1068-1076
37. Monetini L, Cavallo MG, Sarugeri E, Sentinelli F, Stefanini L, Bosi, Thorpe R, Pozzilli P. Cytokine profile and insulin antibody IgG sub-classes in patients with recent onset Type 1 diabetes treated with oral insulin. Diabetologia 2004; 47: 1795-1802
38. Koczwara K, Schenker M, Schmid S, Kredel K, Ziegler AG, Bonifacio E. Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Clin Immunol 2003; 106: 155-162
39. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, Herrath M von. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116: 1371-1381
40. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004; 27: 2695-2700
41. Aly TA, Ide A, Barker JM, Fernando M, Babu SR, Yu L, Miao D, Erlich HA, Fain P, Barriga K, Norris JM, Elsenbarth GS, Rewers MJ. HLA genotype and haplotype sharing determine extremely high risk of early childhood type 1 diabetes. PNAS 2006; 103: 14074-14079
42. Walter M, Albert E, Conrad M et al. IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity. Diabetologia 2003; 46: 712-720
43. Laine AP, Hermann R, Knip M, Simell O, Akerblom HK, Ilonen J. The human leukocyte antigen genotype has a modest effect on the insulin gene polymorphism-associated susceptibility to type 1 diabetes in the Finnish population. Tissue Antigens 2004; 63: 72-74
44. Barker JM, MacFann KK, Orban T. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 2007; 50: 1603-1606
45. Staeva-Vieira T, Peakman M, Herrath M von. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148: 17-31